Evidence map›Paper›PMID 34942994›Full record

ArticleAntioxidants (Basel, Switzerland)2021

Ascorbic Acid Deficiency Prevalence and Associated Cognitive Impairment in Alcohol Detoxification Inpatients: A Pilot Study.

Virgile Clergue-Duval, Julien Azuar, Julien Fonsart, Clément Delage, Dorian Rollet, Jihed Amami, Alexia Frapsauce, Marie-Astrid Gautron, Eric Hispard, Frank Bellivier and 4 more

Open access · goldAbstract read
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Virgile Clergue-DuvalAPHP GHU Nord, Site Lariboisière Fernand-Widal, Département de Psychiatrie et de Médecine Addictologique, 75010 Paris, France.ORCID 0000-0003-2803-8249
Julien AzuarAPHP GHU Nord, Site Lariboisière Fernand-Widal, Département de Psychiatrie et de Médecine Addictologique, 75010 Paris, France.
Julien FonsartAPHP GHU Nord, Site Lariboisière Fernand-Widal, Département de Biochimie et Biologie Moléculaire, 75010 Paris, France.
Clément DelageInserm UMRS-1144 Optimisation Thérapeutique en Neuropsychopharmacologie, Université de Paris, 75006 Paris, France.ORCID 0000-0003-0710-1659
Dorian RolletAPHP GHU Nord, Site Lariboisière Fernand-Widal, Département de Psychiatrie et de Médecine Addictologique, 75010 Paris, France.
Jihed AmamiAPHP GHU Nord, Site Lariboisière Fernand-Widal, Département de Psychiatrie et de Médecine Addictologique, 75010 Paris, France.
Alexia FrapsauceAPHP GHU Nord, Site Lariboisière Fernand-Widal, Service de Pharmacie, 75010 Paris, France.
Marie-Astrid GautronFHU Network of Research in Substance Use Disorders (NOR-SUD), 75006 Paris, France.
Eric HispardAPHP GHU Nord, Site Lariboisière Fernand-Widal, Département de Psychiatrie et de Médecine Addictologique, 75010 Paris, France.
Frank BellivierAPHP GHU Nord, Site Lariboisière Fernand-Widal, Département de Psychiatrie et de Médecine Addictologique, 75010 Paris, France.
Vanessa BlochInserm UMRS-1144 Optimisation Thérapeutique en Neuropsychopharmacologie, Université de Paris, 75006 Paris, France.ORCID 0000-0002-2582-6349
Jean-Louis LaplancheInserm UMRS-1144 Optimisation Thérapeutique en Neuropsychopharmacologie, Université de Paris, 75006 Paris, France.
Frank QuestelAPHP GHU Nord, Site Lariboisière Fernand-Widal, Département de Psychiatrie et de Médecine Addictologique, 75010 Paris, France.
Florence VorspanAPHP GHU Nord, Site Lariboisière Fernand-Widal, Département de Psychiatrie et de Médecine Addictologique, 75010 Paris, France.ORCID 0000-0001-5168-3727
Inserm · FRAssistance Publique – Hôpitaux de Paris · FRFHU Neurovasc · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malnutrition has been reported in alcohol use disorder patients as having a possible influence on cognitive function. The aim of this study was to analyse the prevalence of ascorbic acid (AA) deficiency in inpatients admitted for alcohol detoxification and the associated factors, including cognitive impairment in the early period of abstinence. A retrospective chart review was conducted. The AA level was categorised into three groups: deficiency (AAD) (<2 mg/L), insufficiency (AAI) (2-5 mg/L) and normal level. The cognitive impairment was screened using the Montreal Cognitive Assessment (MoCA). Ninety-six patients were included (74 men; mean age 49.1 years (±11.5)). Twenty-seven AAD (28.1%) and twenty-two AAI (22.9%) were observed. In multivariate analysis, risk factors for AAD versus normal AA level were men (OR 17.8, 95%CI (1.63-194)), compensated cirrhosis (OR 9.35, 95%CI (1.60-54.6)) and street homelessness (OR 5.76, 95%CI (1.24-26.8) versus personal housing). The MoCA score was available for 53 patients (mean MoCA score: 25.7 (±3.3)). In multivariate analysis, the natural logarithm of AA (β = 1.18,

Indexed as

alcohol use disorderascorbic acidcentral nervous systemcognitive impairmentHIVhomeless personsliver cirrhosismalnutritionsedative use disorder

Identifiers

PMID34942994
PMCPMC8750659
OpenAlexW3216094224

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.